Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Grief and CVD: Simple Regimen May Lower Risk

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

November 19, 2019

Dobutamine Stress Echo Ischemia a Predictor of PCI Efficacy in Stable CAD

Presentation

Dobutamine Stress Echo Ischemia a Predictor of PCI Efficacy in Stable CAD

November 14, 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

October 02, 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

September 03, 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

August 31, 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

July 23, 2019

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

News Daily News

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

July 09, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

Analysis Supports Aiming for Lower BP in Patients With Diabetes, Hypertension

News Daily News

Analysis Supports Aiming for Lower BP in Patients With Diabetes, Hypertension

April 29, 2019

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

January 08, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.